Annual Drug Patent Expirations for SAFYRAL
Safyral is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for SAFYRAL.
This drug has sixty-seven patent family members in thirty-eight countries.
The generic ingredient in SAFYRAL is drospirenone; ethinyl estradiol; levomefolate calcium. Two suppliers are listed for this compound. Additional details are available on the drospirenone; ethinyl estradiol; levomefolate calcium profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
